Hypersensitivity reactions (eg, anaphylaxis, rash) may occur following administration. Immediately discontinue in case of serious hypersensitivity reaction (eg, anaphylaxis). Do not inj into areas where skin is tender, bruised, erythematous, or hardened. Asthma-related symptoms or exacerbations may occur during treatment. Do not use to treat acute asthma exacerbations. Abrupt discontinuation of corticosteroids after initiation of therapy is not recommended. Patients w/ pre-existing serious infections &/or pre-existing helminth infections should be treated before initiating tezepelumab therapy. Discontinue therapy in case of serious infection &/or serious cardiac event while receiving treatment. Preferable to avoid use during pregnancy unless expected benefit to pregnant mother is greater than any possible risk to foetus. Risk to breast-fed child cannot be excluded during the 1st few days after birth. Safety & efficacy in childn <12 yr have not been established.
Sign Out
